Does the media favor QNTM or HCWB?

In the previous week, HCW Biologics had 1 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for HCW Biologics and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.33 beat HCW Biologics' score of 0.21 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, HCWB or NCEL?

HCW Biologics has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HCW Biologics $50K 105.62 -$7.96M -$27.60 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Does the media prefer HCWB or KTTA?

In the previous week, HCW Biologics had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for HCW Biologics and 1 mentions for Pasithea Therapeutics. HCW Biologics' average media sentiment score of 0.21 beat Pasithea Therapeutics' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend HCWB or CMMB?

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 945.30%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities research analysts clearly believe HCW Biologics is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer HCWB or CMMB?

In the previous week, HCW Biologics had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 4 mentions for HCW Biologics and 3 mentions for Chemomab Therapeutics. HCW Biologics' average media sentiment score of 0.21 beat Chemomab Therapeutics' score of -0.67 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Is BCDA or HCWB more profitable?

BioCardia has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. HCW Biologics' return on equity of -262.33% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% HCW Biologics -83.03% -262.33% -34.90%

HCW Biologics (HCWB) Competitors

$2.87 -0.49 (-14.58%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$2.84 -0.04 (-1.22%)

As of 05:44 AM Eastern

Compare

HCWB vs. QNTM, NCEL, KTTA, CMMB, and BCDA

Should you buy HCW Biologics stock or one of its competitors? HCW Biologics's main competitors and comparable companies include Quantum Biopharma (QNTM), NLS Pharmaceutics (NCEL), Pasithea Therapeutics (KTTA), Chemomab Therapeutics (CMMB), and BioCardia (BCDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does HCW Biologics compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

In the previous week, HCW Biologics had 1 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for HCW Biologics and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.33 beat HCW Biologics' score of 0.21 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quantum Biopharma has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market.

Quantum Biopharma presently has a consensus target price of $8.00, indicating a potential upside of 171.19%. HCW Biologics has a consensus target price of $30.00, indicating a potential upside of 945.30%. Given HCW Biologics' higher possible upside, analysts clearly believe HCW Biologics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HCW Biologics has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
HCW Biologics	$50K	105.62	-$7.96M	-$27.60	N/A

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 9.1% of HCW Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Quantum Biopharma has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. HCW Biologics' return on equity of -262.33% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
HCW Biologics	-83.03%	-262.33%	-34.90%

Summary

HCW Biologics beats Quantum Biopharma on 10 of the 13 factors compared between the two stocks.

How does HCW Biologics compare to NLS Pharmaceutics?

HCW Biologics (NASDAQ:HCWB) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

NLS Pharmaceutics has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. NLS Pharmaceutics' return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
NLS Pharmaceutics	N/A	N/A	N/A

In the previous week, HCW Biologics had 4 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for HCW Biologics and 0 mentions for NLS Pharmaceutics. HCW Biologics' average media sentiment score of 0.21 beat NLS Pharmaceutics' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Neutral
NLS Pharmaceutics	Neutral

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 945.30%. NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 586.57%. Given HCW Biologics' higher probable upside, research analysts clearly believe HCW Biologics is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.0% of HCW Biologics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

HCW Biologics has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	105.62	-$7.96M	-$27.60	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

HCW Biologics has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

HCW Biologics beats NLS Pharmaceutics on 7 of the 11 factors compared between the two stocks.

How does HCW Biologics compare to Pasithea Therapeutics?

HCW Biologics (NASDAQ:HCWB) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

HCW Biologics has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Pasithea Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Pasithea Therapeutics' return on equity of -49.49% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

In the previous week, HCW Biologics had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for HCW Biologics and 1 mentions for Pasithea Therapeutics. HCW Biologics' average media sentiment score of 0.21 beat Pasithea Therapeutics' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

HCW Biologics has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	105.62	-$7.96M	-$27.60	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

HCW Biologics presently has a consensus target price of $30.00, suggesting a potential upside of 945.30%. Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 416.88%. Given HCW Biologics' higher possible upside, equities analysts plainly believe HCW Biologics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

HCW Biologics beats Pasithea Therapeutics on 9 of the 13 factors compared between the two stocks.

How does HCW Biologics compare to Chemomab Therapeutics?

HCW Biologics (NASDAQ:HCWB) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

HCW Biologics currently has a consensus target price of $30.00, suggesting a potential upside of 945.30%. Given HCW Biologics' stronger consensus rating and higher possible upside, equities research analysts clearly believe HCW Biologics is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Chemomab Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. Chemomab Therapeutics' return on equity of -92.14% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Chemomab Therapeutics	N/A	-92.14%	-82.05%

In the previous week, HCW Biologics had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 4 mentions for HCW Biologics and 3 mentions for Chemomab Therapeutics. HCW Biologics' average media sentiment score of 0.21 beat Chemomab Therapeutics' score of -0.67 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

HCW Biologics has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	105.62	-$7.96M	-$27.60	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A

HCW Biologics has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

HCW Biologics beats Chemomab Therapeutics on 10 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to BioCardia?

BioCardia (NASDAQ:BCDA) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

HCW Biologics has lower revenue, but higher earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	275.04	-$8.23M	-$0.64	N/A
HCW Biologics	$50K	105.62	-$7.96M	-$27.60	N/A

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioCardia has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

In the previous week, HCW Biologics had 4 more articles in the media than BioCardia. MarketBeat recorded 4 mentions for HCW Biologics and 0 mentions for BioCardia. HCW Biologics' average media sentiment score of 0.21 beat BioCardia's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Neutral
HCW Biologics	Neutral

BioCardia has a net margin of 0.00% compared to HCW Biologics' net margin of -83.03%. HCW Biologics' return on equity of -262.33% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
HCW Biologics	-83.03%	-262.33%	-34.90%

BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 2,193.58%. HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 945.30%. Given BioCardia's higher probable upside, analysts plainly believe BioCardia is more favorable than HCW Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioCardia and HCW Biologics tied by winning 7 of the 14 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.16M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.10	12.66	273.29	25.25
Price / Sales	105.62	1,342.79	623.67	97.64
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.71	16.39	12.92	6.14
Net Income	-$7.96M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-16.33%	0.36%	0.60%	-0.27%
1 Month Performance	-20.28%	8.53%	5.72%	0.68%
1 Year Performance	-89.67%	52.66%	25.33%	14.84%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	3.7534 of 5 stars	$2.87 -14.6%	$30.00 +945.3%	-90.0%	$6.16M	$50K	N/A	40	News Coverage
QNTM Quantum Biopharma	2.2841 of 5 stars	$3.07 -6.4%	N/A	-81.2%	$19.65M	N/A	N/A	N/A
NCEL NLS Pharmaceutics	2.3849 of 5 stars	$3.38 -2.9%	$23.00 +580.5%	-83.5%	$19.54M	N/A	N/A	6	Gap Up
KTTA Pasithea Therapeutics	2.4777 of 5 stars	$0.57 +1.8%	$3.00 +426.3%	-32.0%	$19.04M	N/A	N/A	3	News Coverage
CMMB Chemomab Therapeutics	1.114 of 5 stars	$2.59 +12.6%	$25.00 +865.3%	-6.3%	$18.65M	N/A	N/A	20	Negative News Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. QNTM, NCEL, KTTA, CMMB, and BCDA

How does HCW Biologics compare to Quantum Biopharma?

Summary

How does HCW Biologics compare to NLS Pharmaceutics?

Summary

How does HCW Biologics compare to Pasithea Therapeutics?

Summary

How does HCW Biologics compare to Chemomab Therapeutics?

Summary

How does HCW Biologics compare to BioCardia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. QNTM, NCEL, KTTA, CMMB, and BCDA

How does HCW Biologics compare to Quantum Biopharma?

Does the media favor QNTM or HCWB?

Which has more volatility & risk, QNTM or HCWB?

Do analysts recommend QNTM or HCWB?

Which has preferable earnings and valuation, QNTM or HCWB?

Do insiders & institutionals believe in QNTM or HCWB?

Is QNTM or HCWB more profitable?

Summary

How does HCW Biologics compare to NLS Pharmaceutics?

Is HCWB or NCEL more profitable?

Does the media refer more to HCWB or NCEL?

Do analysts prefer HCWB or NCEL?

Do institutionals and insiders hold more shares of HCWB or NCEL?

Which has preferable earnings & valuation, HCWB or NCEL?

Which has more risk and volatility, HCWB or NCEL?

Summary

How does HCW Biologics compare to Pasithea Therapeutics?

Which has more volatility & risk, HCWB or KTTA?

Is HCWB or KTTA more profitable?

Does the media prefer HCWB or KTTA?

Do institutionals & insiders hold more shares of HCWB or KTTA?

Which has better valuation and earnings, HCWB or KTTA?

Do analysts recommend HCWB or KTTA?

Summary

How does HCW Biologics compare to Chemomab Therapeutics?

Do analysts recommend HCWB or CMMB?

Do insiders & institutionals hold more shares of HCWB or CMMB?

Is HCWB or CMMB more profitable?

Does the media prefer HCWB or CMMB?

Which has higher earnings & valuation, HCWB or CMMB?

Which has more risk and volatility, HCWB or CMMB?

Summary

How does HCW Biologics compare to BioCardia?

Which has better earnings and valuation, BCDA or HCWB?

Do institutionals & insiders have more ownership in BCDA or HCWB?

Which has more risk and volatility, BCDA or HCWB?

Does the media favor BCDA or HCWB?

Is BCDA or HCWB more profitable?

Do analysts rate BCDA or HCWB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools